Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V and Investor Communications

This article was originally published in The Pink Sheet Daily

Executive Summary

The Prescription Drug User Fee Act reauthorization made a number of important changes to the new drug review process and programs for stakeholder engagement with FDA. It also created a number of new investor communication challenges for sponsors.

Advertisement

Related Content

As “Breakthrough Therapy” Designations Rise, So Do Disclosure Questions
As “Breakthrough Therapy” Designations Rise, So Do Disclosure Questions
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
FDA’s Drug Review Challenge For 2013: Managing Sponsor Expectations
Breaking Down the First “Breakthrough”
Late-Cycle Approval Predictions Not A Good Idea, FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel